Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area

被引:111
作者
Kresnik, E
Gallowitsch, HJ
Mikosch, P
Stettner, H
Igerc, I
Gomez, I
Kumnig, G
Lind, P
机构
[1] Univ Klagenfurt, Dept Nucl Med & Special Endocrinol, Klagenfurt, Austria
[2] Univ Klagenfurt, Inst Math, Klagenfurt, Austria
关键词
D O I
10.1067/msy.2003.71
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. The aim of this study was to evaluate the usefulness of fluorine-18-fluorodeoxyglucose positron emission tomography (F-18-FDG PET) in the preoperative assessment of suspicious thyroid nodules. Methods. A total of 43 patients were examined before surgical resection. In all patients, imaging was obtained at 70 minutes after the intravenous administration of 180 MBq F-18-FDG. Standard uptake values (SUVs) were calculated. Results. A total of 16 patients with thyroid carcinomas (11 papillary, 3 follicular, 2 anaplastic), 23 thyroid adenomas (11 microfollicular, 10 Hurthle cell, 2 macrofollicular), and 4 patients with degenerative goiter were found. F-18-FDG uptake in Hurthle cell adenoma, thyroid cancer, microfollicular adenoma, degenerative goiter, and macrofollicular adenoma was 4.4 +/- 2.2, 3.7 +/- 1.9, 1.6 +/- 0.3, 1.2 +/- 0.2, and 0.9 +/- 0.1, respectively. Significant differences were observed between thyroid carcinomas and both microfollicular adenomas and degenerative goiters (P < 0.05), and between Hurthle cell adenomas and both microfollicular adenomas as well as degenerative goiter (P < 0.05). For diagnosis of thyroid carcinoma, 100% sensitivity, 63% specificity, and 100% negative predictive value was found when a cutoff value for SUV of 2 was used. Conclusions. Our results indicate that thyroid carcinomas, in contrast to most benign thyroid nodules, demonstrate significantly increased glucose metabolism. F-18-FDG PET is unlikely to differentiate successfully all benign tumors from malignant tumors, but it can help select patients who need surgery, especially if cytology is inconclusive or malignancy cannot be excluded.
引用
收藏
页码:294 / 299
页数:6
相关论文
共 17 条
  • [1] POSITRON EMISSION TOMOGRAPHY OF THYROID MASSES
    ADLER, LP
    BLOOM, AD
    [J]. THYROID, 1993, 3 (03) : 195 - 200
  • [2] BLOOM AD, 1993, SURGERY, V114, P728
  • [3] Blumenfeld W, 1999, DIAGN CYTOPATHOL, V20, P185, DOI 10.1002/(SICI)1097-0339(199904)20:4<185::AID-DC1>3.0.CO
  • [4] 2-F
  • [5] Caruso D, 1991, Endocrinologist, V1, P194
  • [6] Dadan J, 1999, Pol Merkur Lekarski, V7, P185
  • [8] CLINICAL-EVALUATION OF THALLIUM CHLORIDE-201 SCAN FOR THYROID-NODULE
    HARADA, T
    ITO, Y
    SHIMAOKA, K
    TANIGUCHI, T
    MATSUDO, A
    SENOO, T
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1980, 5 (02): : 125 - 130
  • [9] JOENSUU H, 1988, EUR J NUCL MED, V13, P502
  • [10] Technetium-99m tetrofosmin imaging in thyroid diseases: Comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans
    Klain, M
    Maurea, S
    Cuocolo, A
    Colao, A
    Marzano, L
    Lombardi, G
    Salvatore, M
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1996, 23 (12): : 1568 - 1574